Eastern cooperative oncology group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 2, Issue 1, 2002, Pages 43-50

  Marsh, John C ^a,b   Catalano, Paul ^c   Huang, Jie ^c   Graham, David L ^d   Cornfeld, Mark J ^e   O'Dwyer, Peter J ^f   Benson, Al B ^g  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD UNIVERSITY   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Chemotherapy; Dihydrophyrimidine dehydrogenase inhibition

Indexed keywords

5 ETHYNYLURACIL; FLUOROURACIL; 5-ETHYNYLURACIL; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; URACIL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; INCIDENCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; STOMATITIS; VOMITING; COLORECTAL TUMOR; CONFIDENCE INTERVAL; DRUG ADMINISTRATION; LIVER TUMOR; LUNG TUMOR; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; SURVIVAL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; URACIL;

EID: 0036018890     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2002.n.010     Document Type: Article

References (32)

1. Chemotherapy of large bowel cancer
2. Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients
3. Enzymes of uracil catabolism in normal and neoplastic human tissues
4. 5-Ethynyluracil (776C85): Inactivation of dihydropyrimidine dehydrogenase in vivo
5. 5-Ethynyluracil (776C85): A potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil
6. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors
7. 5-Ethynyluracil (776C85): Modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma
8. A phase II trial of 7 days of oral 776C85 plus 5 days of 5-fluorouracil (5FU) in patients (pts) with metastatic colorectal cancer (M-CRC), a North Central Cancer Treatment Group study
9. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer
10. Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline-and taxane-resistant advanced breast cancer
11. Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: A phase II study
12. A multicenter, phase II trial of oral eniluracil plus 5-FU in patients with inoperable hepato-cellular carcinoma
13. A National Cancer Institute of Canada clinical trials group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer
14. Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil
15. Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology
16. Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the mono-fluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine
17. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
18. Capecitabine in colorectal cancer
19. UFT in the treatment of colorectal and breast cancer
20. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer
21. Toxicity and response criteria of the Eastern Cooperative Oncology Group
22. Nonparametric estimation of incomplete observations
23. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer
24. International phase III study of oral eniluracil (EU) plus 5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC)
25. A phase II trial of a seven day regimen of oral 776C85 plus a five day regimen of oral 5-fluorouracil (5-FU) in untreated patients (pts) with metastatic colorectal cancer (M-CRC): A North Central Cancer Treatment Group study
26. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma
27. A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer
28. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer
29. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study
30. A phase III trial of Xeloda™ (capecitabine) in previously untreated advanced/metastatic colorectal cancer
31. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
32. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer